Clinical Trial AVX - 001
Clinical trial AVX-001 is the first study of PVX108 to be conducted in humans. The objectives of this trial are:
to determine the maximum dose that can be safely administered as a single injection
to assess the safety of repeat, escalating doses, administered once every 2 weeks.
Recruitment for clinical trial AVX-001 is now complete.
CMAX Clinical Research
Adelaide, South Australia.
Ph. 1800 150 433
Centre for Clinical Studies
Ph. 03 8593 9875
Are you interested in participating in future trials?